PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635077
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635077
AI-Based Clinical Trials Solution Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
The AI-based clinical trials solution market is experiencing significant growth, with revenues projected to increase from an estimated $2.4 billion in 2024 to $5.4 billion by 2030, reflecting a compound annual growth rate (CAGR) of 14.5% during 2025-2030. This expansion is driven by the increasing prevalence of chronic diseases and the growing demand for advanced drugs. Artificial intelligence (AI) plays a pivotal role in trial design, patient selection and recruitment, site selection, and patient monitoring, aiming to enhance the efficiency and success rates of clinical trials.
Key Insights
Pharmaceutical companies are investing significantly in AI to replenish their pipelines, contributing to market growth. The integration of AI in clinical trials accelerates drug discovery and development processes, reducing time and costs associated with bringing new therapies to market.
The adoption of real-world evidence (RWE) is a key trend in the market. RWE, collected from electronic health records, wearables, patient registries, and social media, enhances trial design and patient recruitment by providing insights into patient populations and treatment outcomes.
Data quality and integrity remain significant challenges. AI systems rely on accurate and comprehensive data for proper analysis and decision-making. Faulty or incomplete data can lead to incorrect results, undermining trust in AI applications.
The phase II clinical trial segment dominated the market with a revenue share of 40% in 2024. This is attributed to the large number of registered validation cases active in this phase and the increasing use of smart technologies for data gathering and analysis.
North America holds the largest market share, driven by the early adoption of advanced technologies and substantial investments in AI research and development. However, the Asia-Pacific region is expected to exhibit the fastest growth during the forecast period, due to increasing digital transformation initiatives and government investments in AI technologies.
The market is fragmented, with numerous technology companies developing AI-driven clinical trial solutions. Continuous innovation and strategic partnerships are essential for companies to maintain a competitive edge in this rapidly evolving market.
Table of Contents
Chapter 1. Research Scope
- 1.1. Research Objectives
- 1.2. Market Definition
- 1.3. Analysis Period
- 1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by clinical trial phase type
- 1.4.2. Market size breakdown, by therapeutic application
- 1.4.3. Market size breakdown, by end user
- 1.4.4. Market size breakdown, by region
- 1.4.5. Market size breakdown, by country
- 1.5. Market Data Reporting Unit
- 1.5.1. Value
- 1.6. Key Stakeholders
Chapter 2. Research Methodology
- 2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
- 2.2. Primary Research
- 2.3. Market Size Estimation
- 2.4. Data Triangulation
- 2.5. Currency Conversion Rates
- 2.6. Assumptions for the Study
- 2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Market Indicators
Chapter 5. Industry Outlook
- 5.1. Market Dynamics
- 5.1.1. Trends
- 5.1.2. Drivers
- 5.1.3. Restraints/challenges
- 5.1.4. Impact analysis of drivers/restraints
- 5.2. Impact of COVID-19
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Bargaining power of buyers
- 5.3.2. Bargaining power of suppliers
- 5.3.3. Threat of new entrants
- 5.3.4. Intensity of rivalry
- 5.3.5. Threat of substitutes
Chapter 6. Global Market
- 6.1. Overview
- 6.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 6.3. Market Revenue, by Therapeutic Application (2019-2030)
- 6.4. Market Revenue, by End User (2019-2030)
- 6.5. Market Revenue, by Region (2019-2030)
Chapter 7. North America Market
- 7.1. Overview
- 7.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 7.3. Market Revenue, by Therapeutic Application (2019-2030)
- 7.4. Market Revenue, by End User (2019-2030)
- 7.5. Market Revenue, by Country (2019-2030)
Chapter 8. Europe Market
- 8.1. Overview
- 8.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 8.3. Market Revenue, by Therapeutic Application (2019-2030)
- 8.4. Market Revenue, by End User (2019-2030)
- 8.5. Market Revenue, by Country (2019-2030)
Chapter 9. APAC Market
- 9.1. Overview
- 9.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 9.3. Market Revenue, by Therapeutic Application (2019-2030)
- 9.4. Market Revenue, by End User (2019-2030)
- 9.5. Market Revenue, by Country (2019-2030)
Chapter 10. LATAM Market
- 10.1. Overview
- 10.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 10.3. Market Revenue, by Therapeutic Application (2019-2030)
- 10.4. Market Revenue, by End User (2019-2030)
- 10.5. Market Revenue, by Country (2019-2030)
Chapter 11. MEA Market
- 11.1. Overview
- 11.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 11.3. Market Revenue, by Therapeutic Application (2019-2030)
- 11.4. Market Revenue, by End User (2019-2030)
- 11.5. Market Revenue, by Country (2019-2030)
Chapter 12. U.S. Market
- 12.1. Overview
- 12.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 12.3. Market Revenue, by Therapeutic Application (2019-2030)
- 12.4. Market Revenue, by End User (2019-2030)
Chapter 13. Canada Market
- 13.1. Overview
- 13.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 13.3. Market Revenue, by Therapeutic Application (2019-2030)
- 13.4. Market Revenue, by End User (2019-2030)
Chapter 14. Germany Market
- 14.1. Overview
- 14.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 14.3. Market Revenue, by Therapeutic Application (2019-2030)
- 14.4. Market Revenue, by End User (2019-2030)
Chapter 15. France Market
- 15.1. Overview
- 15.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 15.3. Market Revenue, by Therapeutic Application (2019-2030)
- 15.4. Market Revenue, by End User (2019-2030)
Chapter 16. U.K. Market
- 16.1. Overview
- 16.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 16.3. Market Revenue, by Therapeutic Application (2019-2030)
- 16.4. Market Revenue, by End User (2019-2030)
Chapter 17. Italy Market
- 17.1. Overview
- 17.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 17.3. Market Revenue, by Therapeutic Application (2019-2030)
- 17.4. Market Revenue, by End User (2019-2030)
Chapter 18. Spain Market
- 18.1. Overview
- 18.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 18.3. Market Revenue, by Therapeutic Application (2019-2030)
- 18.4. Market Revenue, by End User (2019-2030)
Chapter 19. Japan Market
- 19.1. Overview
- 19.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 19.3. Market Revenue, by Therapeutic Application (2019-2030)
- 19.4. Market Revenue, by End User (2019-2030)
Chapter 20. China Market
- 20.1. Overview
- 20.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 20.3. Market Revenue, by Therapeutic Application (2019-2030)
- 20.4. Market Revenue, by End User (2019-2030)
Chapter 21. India Market
- 21.1. Overview
- 21.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 21.3. Market Revenue, by Therapeutic Application (2019-2030)
- 21.4. Market Revenue, by End User (2019-2030)
Chapter 22. Australia Market
- 22.1. Overview
- 22.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 22.3. Market Revenue, by Therapeutic Application (2019-2030)
- 22.4. Market Revenue, by End User (2019-2030)
Chapter 23. South Korea Market
- 23.1. Overview
- 23.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 23.3. Market Revenue, by Therapeutic Application (2019-2030)
- 23.4. Market Revenue, by End User (2019-2030)
Chapter 24. Brazil Market
- 24.1. Overview
- 24.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 24.3. Market Revenue, by Therapeutic Application (2019-2030)
- 24.4. Market Revenue, by End User (2019-2030)
Chapter 25. Mexico Market
- 25.1. Overview
- 25.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 25.3. Market Revenue, by Therapeutic Application (2019-2030)
- 25.4. Market Revenue, by End User (2019-2030)
Chapter 26. Saudi Arabia Market
- 26.1. Overview
- 26.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 26.3. Market Revenue, by Therapeutic Application (2019-2030)
- 26.4. Market Revenue, by End User (2019-2030)
Chapter 27. South Africa Market
- 27.1. Overview
- 27.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 27.3. Market Revenue, by Therapeutic Application (2019-2030)
- 27.4. Market Revenue, by End User (2019-2030)
Chapter 28. U.A.E. Market
- 28.1. Overview
- 28.2. Market Revenue, by Clinical Trial Phase Type (2019-2030)
- 28.3. Market Revenue, by Therapeutic Application (2019-2030)
- 28.4. Market Revenue, by End User (2019-2030)
Chapter 29. Competitive Landscape
- 29.1. List of Market Players and their Offerings
- 29.2. Competitive Benchmarking of Key Players
- 29.3. Product Benchmarking of Key Players
- 29.4. Recent Strategic Developments
Chapter 30. Company Profiles
- 30.1. Recursion Pharmaceuticals
- 30.1.1. Business overview
- 30.1.2. Product and service offerings
- 30.1.3. Key financial summary
- 30.2. nference Inc.
- 30.2.1. Business overview
- 30.2.2. Product and service offerings
- 30.2.3. Key financial summary
- 30.3. Verily Life Sciences LLC
- 30.3.1. Business overview
- 30.3.2. Product and service offerings
- 30.3.3. Key financial summary
- 30.4. Aitia
- 30.4.1. Business overview
- 30.4.2. Product and service offerings
- 30.4.3. Key financial summary
- 30.5. Paradigm Health Inc.
- 30.5.1. Business overview
- 30.5.2. Product and service offerings
- 30.5.3. Key financial summary
- 30.6. Trials.ai
- 30.6.1. Business overview
- 30.6.2. Product and service offerings
- 30.6.3. Key financial summary
- 30.7. Median Technologies
- 30.7.1. Business overview
- 30.7.2. Product and service offerings
- 30.7.3. Key financial summary
- 30.8. Mendel Health Inc.
- 30.8.1. Business overview
- 30.8.2. Product and service offerings
- 30.8.3. Key financial summary
- 30.9. Deep 6 AI Inc.
- 30.9.1. Business overview
- 30.9.2. Product and service offerings
- 30.9.3. Key financial summary
- 30.10. Antidote Technologies Inc.
- 30.10.1. Business overview
- 30.10.2. Product and service offerings
- 30.10.3. Key financial summary
- 30.11. Saama Technologies LLC
- 30.11.1. Business overview
- 30.11.2. Product and service offerings
- 30.11.3. Key financial summary
- 30.12. Unlearn.ai Inc.
- 30.12.1. Business overview
- 30.12.2. Product and service offerings
- 30.12.3. Key financial summary
Chapter 31. Appendix
- 31.1. Abbreviations
- 31.2. Sources and References
- 31.3. Related Reports
